ERBB2 and breast cancer: An oral SERD, elacestrant, received Food and Drug Administration (FDA) approval for second-line use in HR+/HER2-locally advanced or metastatic BC with ESR1 mutations in January 2023 [21] based on data from the phase 3 EMERALD trial (NCT03778931) [22].